A Phase 3, Randomized, Double Blind Placebo Controlled Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects with Active Crohn's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date8/12/166/30/18

Funding

  • Celgene: $17,262.00